文献速递心血管PET

转甲状腺素蛋白心脏淀粉样变性诊断预测模型与评分的开发与验证:T-Amylo

Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo.
PubMed 文献 · JACC Cardiovasc Imaging · 2023-06-28

这项回顾性多中心研究基于227例推导样本开发了结合年龄、性别、腕管综合征、舒张期室间隔厚度和低QRS电压的T-Amylo预测模型与简化评分,并在11个中心895例外部队列中验证;模型AUC在推导样本为0.92、验证样本为0.84,评分分别为0.86和0.82,在高血压心肌病、重度主动脉瓣狭窄和射血分数保留的心力衰竭三种临床场景中均显示良好诊断准确性。

要点

  • T-Amylo模型联合年龄、性别、腕管综合征、舒张期室间隔厚度和低QRS电压预测ATTR-CA。
  • 模型AUC推导样本0.92、验证样本0.84;评分AUC推导样本0.86、验证样本0.82。
  • 在高血压心肌病、重度主动脉瓣狭窄和射血分数保留的心力衰竭场景中均显示良好诊断准确性。

核心结论

  • T-Amylo是一个简单的预测模型,可改善疑似ATTR-CA患者的诊断预测。

研究设计与样本

  • 回顾性多中心研究,推导样本为来自2个中心的227例连续患者,外部队列来自11个中心的895例,均因疑似ATTR-CA接受99mTc-DPD闪烁显像。

诊断标准与关键数值

  • ATTR-CA诊断标准为99mTc-DPD闪烁显像显示2级或3级心肌摄取且无可检测的单克隆成分,或活检证实淀粉样物质。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Although transthyretin cardiac amyloidosis (ATTR-CA) is often underdiagnosed, clinical suspicion is essential for early diagnosis.

OBJECTIVES: The aim of this study was to develop and validate a feasible prediction model and score to facilitate the diagnosis of ATTR-CA.

METHODS: This retrospective multicenter study enrolled consecutive patients who underwent 99mTc-DPD scintigraphy for suspected ATTR-CA. ATTR-CA was diagnosed if Grade 2 or 3 cardiac uptake was evidenced on 99mTc-DPD scintigraphy in the absence of a detectable monoclonal component or by demonstration of amyloid by biopsy. A prediction model for ATTR-CA diagnosis was developed in a derivation sample of 227 patients from 2 centers using multivariable logistic regression with clinical, electrocardiography, analytical, and transthoracic echocardiography variables. A simplified score was also created. Both of them were validated in an external cohort (n = 895) from 11 centers.

RESULTS: The obtained prediction model combined age, gender, carpal tunnel syndrome, interventricular septum in diastole thickness, and low QRS interval voltages, with an area under the curve (AUC) of 0.92. The score had an AUC of 0.86. Both the T-Amylo prediction model and the score showed a good performance in the validation sample (ie, AUC: 0.84 and 0.82, respectively). They were tested in 3 clinical scenarios of the validation cohort: 1) hypertensive cardiomyopathy (n = 327); 2) severe aortic stenosis (n = 105); and 3) heart failure with preserved ejection fraction (n = 604), all with good diagnostic accuracy.

CONCLUSIONS: The T-Amylo is a simple prediction model that improves the prediction of ATTR-CA diagnosis in patients with suspected ATTR-CA.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Arana-Achaga, Goena-Vives, Villanueva-Benito, et al. Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo. JACC Cardiovasc Imaging. 2023. PMID: 37389511. doi:10.1016/j.jcmg.2023.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。